Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Distribute Whatman's DNA-Storage Technology

NEW YORK (GenomeWeb News) — Qiagen said yesterday that it will distribute Whatman's FTA DNA-handling products under a non-exclusive agreement.
 
Under the agreement, Qiagen will pay an upfront fee and royalties for the rights to sell the kits in the life science research, molecular diagnostics, and applied-testing markets.
 
The royalty payments will apply to all Qiagen sales that incorporate Whatman's products.
 
Whatman's FTA instruments and FTA-based kits use "a chemically treated matrix" that lyses cells, immobilizes nucleic acids, and allows researchers to collect, transport, archive, and release DNA at room temperature.
 
Qiagen said the FTA line is "highly synergistic" with its sample-prep technology portfolio, and that it expects the combination of tools to be useful in forensics, pharmacogenomics, biobanking, and genomics research.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.